| Code | CSB-RA723415MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Oleclumab, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is a cell surface glycoprotein that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E contributes to immunosuppression through inhibition of T cell and NK cell function while promoting regulatory T cell activity. Elevated NT5E expression has been associated with various malignancies, including triple-negative breast cancer, ovarian cancer, and melanoma, where it correlates with poor prognosis and resistance to immunotherapy.
Oleclumab is a humanized IgG1 monoclonal antibody designed to block NT5E enzymatic activity, thereby reducing adenosine-mediated immunosuppression in the tumor microenvironment. This biosimilar antibody serves as a valuable research tool for investigating adenosine pathway mechanisms, exploring combination immunotherapy strategies, and studying NT5E biology in cancer and immune-related disorders. It enables researchers to evaluate checkpoint inhibition beyond traditional PD-1/PD-L1 pathways.
There are currently no reviews for this product.